Endotyping-informed therapy for patients with chest pain and no obstructive coronary artery disease: a randomized trial.

Name: Αlpha¹ Rigor Record — Endotyping-informed therapy for patients with chest pain and no obstructive coronary artery disease: a randomized trial.
Item: Endotyping-informed therapy for patients with chest pain and no obstructive coronary artery disease: a randomized trial.
Rating: 100
Author: Αlpha¹

Bradley CP, McKinley G, Orchard V, Tiller C, Stanley B, Ang D, Morrow AJ, Sykes R, Gildea P, Petty M, Brogan R, Carrick D, Collison D, Eteiba H, Ghattas A, Good R, Joshi F, Lindsay M, McCartney P, McGowan J, McGeoch R, Robertson K, Rocchiccioli P, Shaukat A, Watkins S, Kellman P, McConnachie A, Berry C

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 2.5★ (Weak), 0 critical, 3 high issues for “Endotyping-informed therapy for patients with chest pain and no obstructive coronary artery disease: a randomized trial.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 15, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

2.5 / 5

Weak — serious problems found

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×3−1.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Problems surfaced5 types

Numerical inconsistencies1

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Overstated conclusions3

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions only partially backed by the presented evidenceAssessed

Data authenticity concerns1

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Other integrity concernAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted and well-reported randomized controlled trial. The study design is rigorous with proper randomization, blinding, and a prespecified analysis plan. Minor reporting issues include a retrospective registration gap, a rounding discrepancy in the abstract, and a formatting error in the data availability statement.

Both reviewers classified the study as interventional, which is adopted. The evaluation covers all eight dimensions; no dimensions were excluded as not applicable. The reviewers agreed on all dimensions; no divergence required resolution.

6 major claims checked against the paper's own evidence: 1 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Recomputed 1 test: 1 consistent, 0 inconsistent; 1 via agent-written checks.

3 integrity concerns flagged (0 high).

Reporting

Eight Dimensions8 pass

The introduction cites multiple prior studies and guidelines establishing the diagnostic challenge of ANOCA and the potential of functional testing. The rationale for using CMR to endotype patients is clearly linked to the hypothesis that CMR-guided management improves diagnosis and symptoms. Limitations of prior research (e.g., lack of randomized trials for CMR) are explicitly addressed.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise with extensive prior work cited and a logical rationale linking the premise to the study objectives.

Evidence

direct quote[Introduction, paragraph 1-2]

“The Coronary Microvascular Angina (CorMicA) trial demonstrated that coronary function testing during invasive management of suspected ANOCA is associated with improvements in symptoms, health-related quality of life and health economics . These results were recently validated in the ILIAS ANOCA trial .”